Detalhe da pesquisa
1.
A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
Gynecol Oncol
; 156(3): 535-544, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31924332
2.
Data on prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer: Post-hoc data analysis from the phase 3 randomized, open-label study comparing trabectedin and PLD versus PLD alone in patients with recurrent ovarian cancer.
Data Brief
; 30: 105465, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32346557
3.
Development of novel substrates for tumor immunotherapy.
J Control Release
; 91(1-2): 209-24, 2003 Aug 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-12932653
4.
Absorbable microparticulate cation exchanger for immunotherapeutic delivery.
J Biomed Mater Res B Appl Biomater
; 69(2): 173-82, 2004 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15116407
5.
Injectable in situ forming controlled release implant composed of a poly-ether-ester-carbonate and applications in the field of chemotherapy.
J Biomed Mater Res A
; 100(9): 2365-72, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22528373